Truist lowered the firm’s price target on SI-Bone to $24 from $26 and keeps a Buy rating on the shares. The company’s Q4 gross margin miss was unexpected but driven by a “transitory” item, and the Si-Bone looks primed to beat and raise guidance through 2024, the analyst tells investors in a research note. The firm adds that it would buy the stock on weakness.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SIBN:
- SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
- SIBN Earnings this Week: How Will it Perform?
- SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
- SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
- SI-Bone receives FDA 510k clearance for smaller diameter of iFuse Implant
